<DOC>
	<DOCNO>NCT02624128</DOCNO>
	<brief_summary>V-CHANCE phase 2 , trial explore feasibility activity valproic acid ( VPA ) combination standard cisplatin-cetuximab combination patient recurrent/metastatic squamous cell carcinoma head neck , never treat first-line chemotherapy . The study include explorative analysis potential prognostic predictive role several biomarkers aim improve knowledge mechanism VPA enhance chemotherapy effect identify early predictor treatment response/resistance .</brief_summary>
	<brief_title>Valproic Acid Plus Cisplatin Cetuximab Recurrent and/or Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Histologically cytologically proven squamous cell carcinoma head neck exclusion nasopharynx 2 . Firstline recurrent and/or metastatic disease 3 . No prior chemotherapy except chemoradiation induction chemotherapy follow local treatment give context curative strategy . 4. age &gt; 18 year 5 . ECOG Performance Status ≤1 6 . Life expectancy least 3 month study entrance 7 . Normal bone marrow reserve ( absolute neutrophil count &gt; 1500/mm3 ; platelet &gt; 100000/mm3 ; haemoglobin &gt; 9 g/dl ) 8 . Normal hepatic function ( total serum bilirubin &lt; 1.5 x upper limit normal ; liver transaminases &lt; 3 x upper limit normal ) 9 . Normal renal function ( serum creatinine &lt; 1,25 x upper limit normal creatinine clearance &gt; 60 ml/min ) . 10 . Normal cardiac function ( assessed ECG echocardiography ejection fraction &gt; 50 % ) 11 . Effective contraception male female patient risk conception exist 12 . Signed write informed consent 1 . Concomitant treatment experimental drug . 2 . Brain metastasis ( CT scan MRI require case clinical suspicion CNS metastases ) 3 . Non squamous cell histology 4 . Any concurrent malignancy . Patient previous malignancy without evidence disease 5 year allow enter trial . 5 . History myocardial infarction within last 12 month 6 . ECOG PS ≥ 2 7 . Significant cardiovascular comorbidity ( e.g . myocardial infarction , superior vena cava [ SVC ] syndrome , patient ejection fraction &lt; 50 % ) presence cardiac disease opinion Investigator increase risk ventricular arrhythmia . 8 . History arrhythmia ( multifocal premature ventricular contraction [ PVCs ] , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia . Patients long QTsyndrome QTc interval duration &gt; 480 msec concomitant medication drug prolong QTc . 9 . HIV positive patient 10 . Patients take oral medication , require intravenous feeding , prior surgical procedure affect absorption , active peptic ulcer disease . 11 . Known suspected hypersensitivity study drug . 12 . Patients prior treatment HDAC inhibitor patient receive compound HDAC inhibitorlike activity , valproic acid . 13 . Major surgical procedure within 28 day prior study treatment start . 14 . Pregnant lactating woman . 15 . Women childbearing potential either positive pregnancy test baseline ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) l. 16 . Sexually active male female ( childbearing potential ) unwilling practice contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>valproic acid</keyword>
	<keyword>recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>